*UniSA Clinical and Health Sciences, University of South Australia, Adelaide, Australia;
†UniSA Creative, University of South Australia, Adelaide, Australia;
‡School of Medicine, University of Adelaide, Adelaide, Australia;
§Pharmacy Department, Royal Adelaide Hospital, Adelaide, Australia;
¶School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia;
‖Department of Clinical Pharmacology and Toxicology, St Vincent's Hospital, Sydney, Australia; and
**St Vincent's Clinical School, Faculty of Medicine, The University of New South Wales, Sydney, Australia.
Correspondence: Sherilyn Wong, UniSA Clinical and Health Sciences, University of South Australia, GPO Box 2471, Adelaide, SA 5001, Australia (e-mail: [email protected])
This study was funded by a University of South Australia Research Themes Investment Scheme (RTIS) project grant. The Australian Government is acknowledged for supporting this research by awarding an Australian Government Research Training Program (RTP) PhD Scholarship to S.W. Work undertaken by S. E. Reuter is with the financial support of Cancer Council's Beat Cancer Project on behalf of its donors, the State Government through the Department of Health, and the Australian Government through the Medical Research Future Fund.
The authors declare no conflict of interest.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.drug-monitoring.com).
